Long acting GLP-1 receptor agonist (injectable)
Polyethylene glycol loxenatide 300 µg injection once weekly
PEGLOX_SC_300UG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.51 (-1.00 to -0.01) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -9.16 (-13.29 to -5.04) | 0.96 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.33 (0.69 to 7.47) | 0.28 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.56 (0.01 to 44.67) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 40.40) | 0.68 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.57 (0.01 to 42.21) | 0.57 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD 1.34 (-8.59 to 10.82) | 0.28 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 7.22 (1.47 to 37.35) | 0.70 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 10.71 (2.27 to 42.21) | 0.70 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.09 (0.32 to 15.35) | 0.54 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.87 (0.09 to 35.30) | 0.55 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.12 (0.00 to 1.86) | 0.93 |